Business Context and Reporting Period
This Form 8-K Current Report was filed by Dermata Therapeutics, Inc. on May 14, 2024. The report details a material corporate action approved by the Board of Directors and stockholders to implement a reverse stock split of the Company's common stock.
Key Financial Metrics
This filing is a current report regarding a corporate governance action and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The primary material change reported is the implementation of a one-for-fifteen (1:15) reverse stock split. Key details include:
- Effective Date: The split will take effect at 12:01 a.m. Eastern Time on May 16, 2024.
- Trading Adjustment: Common stock (Ticker: DRMA) is expected to begin trading on a split-adjusted basis on Nasdaq when the market opens on May 16, 2024, subject to approval.
- Share Conversion: Every 15 shares of outstanding common stock will be converted into 1 share.
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive a proportional cash payment.
- Securities Adjustment: All outstanding options and warrants will be adjusted proportionally.
- CUSIP Change: The CUSIP number for the Common Stock will change to 249845405.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard implications of a reverse stock split. The action was authorized by stockholders at the 2024 Annual Meeting on May 7, 2024, who granted the Board discretion to set a ratio between 1:5 and 1:30; the Board selected 1:15.
Investor Verification Checklist
- Verify the new CUSIP number (249845405) for the Common Stock.
- Confirm the trading status of DRMA on Nasdaq on May 16, 2024, to ensure the split-adjusted price is reflected.
- Review the terms of any outstanding stock options or warrants to confirm the adjustment ratio applied to exercise prices and share counts.
- Check brokerage accounts for the receipt of cash payments in lieu of fractional shares if applicable.